Is Basilea Pharmaceutica AG (BSLN.SW) a Buy, Sell, or Hold?
SIX : BSLN.SW
Basilea Pharmaceutica AG
$50.5 CHF
-$0.5 (-0.98%)
- Volume
- 24.96K
- Average Volume
- 23.53K
- Market Capitalization
- $625.02M
- P/E Ratio
- 19.06
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $59.20
- Year Low
- $44.70
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $5.11
Company Overview
SIX
David Veitch
Biotechnology
Healthcare
BSLN.SW
189
CH
CHF
Liquidity Metrics
0.70
5.11
4.68
0.60
0.00
Sales & Valuation
$232.4M
3.46
4.82
12.99
3.94
Profitability
$3.14
$40.2M
17.90%
20.08%
27.95%
11.45%
P/E Metrics
19.06
-0.35
-0.35
Analyst Price Target & Rating
3/5
0 Analysts
%
Financial Health Scores
1.56
8/9
$202.52M
$282M
$154.06M
$101.4M
Key Metrics (TTM)
No key metrics data available.
Company Executives
| Name | Title |
|---|---|
| Laurenz Kellenberger | Chief Scientific Officer |
| Gerrit Hauck | Chief Technology Officer |
| Adesh Kaul | Chief Financial Officer |
| David Veitch | Chief Executive Officer |
| Mark Jones | Head of Global Affairs |
| Peer Nils Schroder | Head of Corporate Communications & Investor Relations |
| Ursula Eberhardt | Head of Global Human Resources |
| Marc Engelhardt | Chief Medical Officer |
| Andreas Kumin | Head of Corporate Development |
| Damian Heller | General Counsel & Corporate Secretary |
Poll Results
No votes yet today — be the first to share your view!
About Basilea Pharmaceutica AG (SIX:BSLN.SW) Stock
Basilea Pharmaceutica AG operates as a commercial-stage biopharmaceutical enterprise, concentrating its efforts on inventing and advancing treatments to address critical unmet medical needs within the therapeutic fields of oncology and anti-infectives. Its commercialized offerings include Cresemba, an azole antifungal drug available in both intravenous and oral formulations, utilized for managing invasive aspergillosis and mucormycosis in the United States and the European Union; this drug is also advancing through Phase III clinical trials in Japan for various invasive fungal infections. The company additionally provides Zevtera, an antibiotic targeting community and hospital-acquired pneumonia, which is also undergoing Phase III clinical development for acute bacterial skin and skin stru ... cture infections, along with Staphylococcus aureus bacteremia. Beyond its current portfolio, Basilea's pipeline features Derazantinib, a small molecule inhibitor in Phase 2 clinical trials for bile duct cancer, and in Phase 1/2 trials for both bladder and stomach cancers, as well as Lisavanbulin, a novel tumor checkpoint controller drug. Established in 2000, Basilea Pharmaceutica AG maintains its corporate headquarters in Basel, Switzerland.
2026-05-28 01:15:00
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, May 28, 2026 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.
2026-05-28 01:15:00
Ad hoc-Mitteilung gemäss Art. 53 KR Allschwil, 28. Mai 2026 Basilea Pharmaceutica AG, Allschwil (SIX: BSLN), ein biopharmazeutisches Unternehmen mit bereits vermarkteten Produkten und dem Ziel, Patientinnen und Patienten zu helfen, die an schweren Infektionen durch Bakterien oder Pilze erkrankt sind, gab heute bekannt, dass die Biomedical Advanced Research and Development Authority (BARDA) der Administration for Strategic Preparedness and Response (ASPR) im US-Gesundheitsministerium Basilea Fördergelder von weiteren USD 13.
Frequently Asked Questions
-
What is the current Basilea Pharmaceutica AG (BSLN.SW) stock price?
-
Basilea Pharmaceutica AG(SIX:BSLN.SW) stock price is $50.5 in the last trading session. During the trading session, BSLN.SW stock reached the peak price of $59.2 while $44.7 was the lowest point it dropped to. The percentage change in BSLN.SW stock occurred in the recent session was --0.98% while the dollar amount for the price change in BSLN.SW stock was -$0.5.
-
BSLN.SW's industry and sector of operation?
-
The SIX listed BSLN.SW is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of BSLN.SW?
-
Laurenz Kellenberger | Chief Scientific Officer
Gerrit Hauck | Chief Technology Officer
Adesh Kaul | Chief Financial Officer
David Veitch | Chief Executive Officer
Mark Jones | Head of Global Affairs -
How many employees does BSLN.SW have?
-
Number of BSLN.SW employees currently stands at 189. BSLN.SW operates from Grenzacherstrasse 487, Allschwil, BL 4058, CH.
-
Link for BSLN.SW official website?
-
Official Website of BSLN.SW is: https://www.basilea.com
-
How do I contact BSLN.SW?
-
BSLN.SW could be contacted at phone #41 61 606 11 11 and can also be accessed through its website. BSLN.SW operates from Grenzacherstrasse 487, Allschwil, BL 4058, CH.
-
How many shares of BSLN.SW are traded daily?
-
The average number of BSLN.SW shares traded daily for last 3 months was 23.53K.
-
What is the market cap of BSLN.SW currently?
-
The market value of BSLN.SW currently stands at $625.02M with its latest stock price at $50.5